News | October 13, 2025
Cadila launches allergy relief tablet Dlorfast-M
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
Merck will showcase results in innovative solutions in HIV treatment and prevention
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
Panacea Biotec receives acceptance from CMSS for supply of bOPV
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
Marks first international filing for Evofem’s single-dose oral treatment
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Panacea Biotec receives Rs. 315 crore LoA from UNICEF
If approved, tavapadon will enhance AbbVie's leadership in Parkinson's disease by providing patients with a once daily oral treatment option
Subscribe To Our Newsletter & Stay Updated
